Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Atsumi Taguchi"'
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 34, Iss , Pp 100952- (2023)
Fabry disease (FD) is an inherited disease caused by deficient α-galactosidase A activity that is characterized by the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). Although plasma lyso-Gb3 is a sensitive bioma
Externí odkaz:
https://doaj.org/article/38dab95368984adf9cc969b76835e9a4
Autor:
Hiroki Maruyama, Atsumi Taguchi, Mariko Mikame, Atsushi Izawa, Naoki Morito, Kazufumi Izaki, Toshiyuki Seto, Akifumi Onishi, Hitoshi Sugiyama, Norio Sakai, Kenji Yamabe, Yukio Yokoyama, Satoshi Yamashita, Hiroshi Satoh, Shigeru Toyoda, Michihiro Hosojima, Yumi Ito, Ryushi Tazawa, Satoshi Ishii
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 1, Pp 389-404 (2021)
Fabry disease is an X-linked disorder of α-galactosidase A (GLA) deficiency. Our previous interim analysis (1 July 2014 to 31 December 2015) revealed plasma globotriaosylsphingosine as a promising primary screening biomarker for Fabry disease proban
Externí odkaz:
https://doaj.org/article/b772c007d4b741eca470f621bcdfd666
Autor:
Hiroki Maruyama, Atsumi Taguchi, Mariko Mikame, Hongmei Lu, Norihiro Tada, Muneaki Ishijima, Haruka Kaneko, Mariko Kawai, Sawako Goto, Akihiko Saito, Riuko Ohashi, Yuji Nishikawa, Satoshi Ishii
Publikováno v:
FASEB BioAdvances, Vol 2, Iss 6, Pp 365-381 (2020)
Abstract Low bone mineral density (BMD)—diagnosed as osteoporosis or osteopenia—has been reported as a new characteristic feature of Fabry disease; however, the mechanism underlying the development of low BMD is unknown. We previously revealed th
Externí odkaz:
https://doaj.org/article/fcee537cb437432cbb0f55503ce4611a
Autor:
Mariko Mikame, Riuko Ohashi, Yuji Nishikawa, Haruka Kaneko, Muneaki Ishijima, Sawako Goto, Norihiro Tada, Atsumi Taguchi, Hiroki Maruyama, Mariko Kawai, Satoshi Ishii, Akihiko Saito, Hongmei Lu
Publikováno v:
FASEB BioAdvances, Vol 2, Iss 6, Pp 365-381 (2020)
FASEB BioAdvances
FASEB BioAdvances
Low bone mineral density (BMD)—diagnosed as osteoporosis or osteopenia—has been reported as a new characteristic feature of Fabry disease; however, the mechanism underlying the development of low BMD is unknown. We previously revealed that a mous
Publikováno v:
The Journal of Biological Chemistry
Fabry disease is a heritable lipid disorder caused by the low activity of α-galactosidase A and characterized by the systemic accumulation of globotriaosylceramide (Gb3). Recent studies have reported a structural heterogeneity of Gb3 in Fabry diseas
Autor:
Mariko Mikame, Kenji Yamabe, Hiroshi Satoh, Toshiyuki Seto, Shigeru Toyoda, Hiroki Maruyama, Hitoshi Sugiyama, Norio Sakai, Akifumi Onishi, Michihiro Hosojima, Naoki Morito, Yukio Yokoyama, Satoshi Yamashita, Atsushi Izawa, Kazufumi Izaki, Satoshi Ishii, Atsumi Taguchi, Ryushi Tazawa, Yumi Ito
Publikováno v:
Current Issues in Molecular Biology
Volume 43
Issue 1
Pages 32-404
Current Issues in Molecular Biology, Vol 43, Iss 32, Pp 389-404 (2021)
Volume 43
Issue 1
Pages 32-404
Current Issues in Molecular Biology, Vol 43, Iss 32, Pp 389-404 (2021)
Fabry disease is an X-linked disorder of α-galactosidase A (GLA) deficiency. Our previous interim analysis (1 July 2014 to 31 December 2015) revealed plasma globotriaosylsphingosine as a promising primary screening biomarker for Fabry disease proban
Autor:
Hiroki Maruyama, Satoshi Ishii, Masaru Shimura, Takeshi Inoue, Mariko Mikame, Gaku Matsukura, Tsuyoshi Shiga, Kenichiro Hanawa, Ryushi Tazawa, Atsumi Taguchi, Mimiko Matsumura, Mio Ebato, Jun Kajihara, Ichijiro Murata, Saori Yamamoto, Satoshi Yamashita, Hitoshi Sugiyama, Kei Murayama, Kaori Miyata, Teiko Sakai, Koichi Tamita, Chu Guili, Toshihiro Kawasaki, Shigeru Toyoda, Hiroshi Satoh, Koichiro Sugimura, Takamasa Oda, Akifumi Onishi, Shigehisa Ura, Takeo Fujimura, Hideki Takano
Publikováno v:
Genetics in Medicine
Purpose Plasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females. Met
Autor:
Masaaki Nameta, Naofumi Imai, Yumi Ito, Ichiei Narita, Yutaka Yamaguchi, Hiroki Maruyama, Yuji Nishikawa, Satoshi Ishii, Mitsuhiro Ueno, Takahiko Nakagawa, Mariko Mikame, Chu Guili, Atsumi Taguchi
Publikováno v:
The FASEB Journal. 32:4544-4559
A main feature of Fabry disease is nephropathy, with polyuria an early manifestation; however, the mechanism that underlies polyuria and affected tubules is unknown. To increase globotriaosylceramide (Gb3) levels, we previously crossbred asymptomatic
Autor:
Hiroki, Maruyama, Atsumi, Taguchi, Yuji, Nishikawa, Chu, Guili, Mariko, Mikame, Masaaki, Nameta, Yutaka, Yamaguchi, Mitsuhiro, Ueno, Naofumi, Imai, Yumi, Ito, Takahiko, Nakagawa, Ichiei, Narita, Satoshi, Ishii
Publikováno v:
The FASEB Journal
A main feature of Fabry disease is nephropathy, with polyuria an early manifestation; however, the mechanism that underlies polyuria and affected tubules is unknown. To increase globotriaosylceramide (Gb3) levels, we previously crossbred asymptomatic
Autor:
Mariko Mikame, Masaru Shimura, Gaku Matsukura, Takeo Fujimura, Akifumi Onishi, Toshihiro Kawasaki, Hitoshi Sugiyama, Hiroshi Satoh, Tsuyoshi Shiga, Mio Ebato, Kei Murayama, Takamasa Oda, Teiko Sakai, Satoshi Yamashita, Satoshi Ishii, Takeshi Inoue, Chu Guili, Saori Yamamoto, Kenichiro Hanawa, Ryushi Tazawa, Hiroki Maruyama, Jun Kajihara, Koichiro Sugimura, Atsumi Taguchi, Shigehisa Ura, Kaori Miyata, Shigeru Toyoda, Koichi Tamita, Ichijiro Murata, Mimiko Matsumura, Hideki Takano
Publikováno v:
Genetics in Medicine
Plasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females.Between 1 Ju